2022
Treatment exposure-based risk-stratification for care of survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.
Dinan M, Stratton K, Leisenring W, Yasui Y, Chow E, Moskowitz C, Yeh J, Noyd D, Armstrong G, Oeffinger K. Treatment exposure-based risk-stratification for care of survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Journal Of Clinical Oncology 2022, 40: 10056-10056. DOI: 10.1200/jco.2022.40.16_suppl.10056.Peer-Reviewed Original ResearchChildhood Cancer Survivor StudyHigh-risk groupHigh-risk survivorsCancer Survivor StudyRisk groupsGrade 3Hazard ratioRisk survivorsAge 20Cumulative incidenceChronic conditionsSurvivor StudyChildhood cancerAge 35Treatment exposureLow-risk survivorsFive-year survivorsHigh-risk patientsRisk stratification algorithmConfidence intervalsProportional hazards modelLong-term surveillanceCare of survivorsLate mortalityPrimary endpoint
2017
Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset
Harowicz MR, Robinson TJ, Dinan MA, Saha A, Marks JR, Marcom PK, Mazurowski MA. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset. Breast Cancer Research And Treatment 2017, 162: 1-10. PMID: 28064383, PMCID: PMC5909985, DOI: 10.1007/s10549-016-4093-4.Peer-Reviewed Original ResearchConceptsIntermediate-risk diseaseOncotype DX recurrence scoreHigh-risk diseaseDX recurrence scoreODX RSReceptor statusRecurrence scoreSurrogate markerProgesterone receptor statusInvasive breast cancerEstrogen receptor statusHigh-risk groupOngoing clinical trialsMagee EquationsPresence of patientsAdjuvant chemotherapyClinicopathologic dataRetrospective studyTumor sizeHER2 statusHistopathologic variablesClinical trialsBreast cancerPatient managementAdditional independent validation
2015
Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing
Roberts MC, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Troester MA, Carey LA, Wheeler SB. Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing. Breast Cancer Research And Treatment 2015, 153: 191-200. PMID: 26216535, PMCID: PMC4562432, DOI: 10.1007/s10549-015-3518-9.Peer-Reviewed Original ResearchConceptsAdjuvant chemotherapy initiationChemotherapy initiationRisk scoreODX testingCarolina Breast Cancer StudyIntermediate-risk groupRacial variationBreast cancer patientsPopulation-based studyHigh-risk groupLarger tumor sizeLow-risk groupOncotype DX testingRacial differencesNorth Carolina womenBreast Cancer StudyAdjuvant chemotherapyTumor sizeCancer patientsRelative riskRisk groupsBreast cancerPoisson regressionYounger agePhase III